Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inulin-type fructans are a **non-digestible prebiotic fiber mixture** composed mainly of inulin and shorter-chain fructooligosaccharides/oligofructose that is administered orally to modulate the gut microbiota rather than to act through a single receptor target. In the provided human studies, ITF was used as a nutritional intervention in adults with overweight or obesity, including a randomized placebo-controlled trial in obese women receiving 16 g/day for 3 months, where treatment increased **Bifidobacterium** species and *Faecalibacterium prausnitzii*, reduced circulating lipopolysaccharide-associated metabolic endotoxemia, and was associated with modest changes in adiposity and metabolic markers. ITF is better characterized as a **dietary prebiotic/nutraceutical ingredient** than a conventional pharmaceutical asset; it has also been studied in snack-bar formulations with whey protein for appetite control and, in separate nonclinical work, in obesity-associated inflammation models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inulin-type fructans.